Bari, Italy
Bari, Italy

Time filter

Source Type

Filiberti R.,IRCCS AOU San Martino IST Instituto Nazionale per la Ricerca sul Cancro | Fontana V.,IRCCS AOU San Martino IST Instituto Nazionale per la Ricerca sul Cancro | De Ceglie A.,Digestive Endoscopy | Blanchi S.,General Hospital | And 9 more authors.
Cancer Causes and Control | Year: 2015

Purpose: To evaluate the role of smoking in Barrett’s esophagus (BE) and erosive esophagitis (E) compared to endoscopic controls with no BE or E. Smoking is considered a cause of both BE and E, but results on this topic are quite controversial. Methods: Patients with BE (339), E (462) and controls (619: 280 with GERD (gastroesophageal reflux disease)-negative and 339 with GERD-positive anamnesis) were recruited in 12 Italian endoscopy units. Data were obtained from structured questionnaires. Results: Among former smokers, a remarkable upward linear trend was found in BE for all smoking-related predictors. In particular, having smoked for more than 32 years increased the risk more than two times (OR 2.44, 95 % CL 1.33–4.45). When the analysis was performed in the subgroup of subjects with GERD-negative anamnesis, the risk of late quitters (<9 years) passed from OR 2.11 (95 % CL 1.19–3.72) to OR 4.42 (95 % CL 1.52–12.8). A noticeably positive dose–response relationship with duration was seen also among current smokers. As regards E, no straightforward evidence of association was detected, but for an increased risk of late quitters (OR 1.84, 95 % CL 1.14–2.98) in former smokers and for early age at starting (OR 3.63, 95 % CL 1.19–11.1) in GERD-negative current smokers. Conclusions: Smoking seems to be an independent determinant of BE and, to a lesser degree, of E. The elevation in risk is independent from GERD and is already present in light cigarette smokers. Smoking cessation may reduce, but not remove this risk. © 2014, Springer International Publishing Switzerland.


News Article | December 8, 2016
Site: www.prnewswire.co.uk

NORWALK, Connecticut, 8. Dezember 2016 /PRNewswire/ -- Mederi Therapeutics Inc. hat die behördliche Zulassung durch die CFDA sowie die Produkteinführung der Stretta-Therapie – eine nicht-operative Behandlungsmethode für gastroösophageale Refluxerkrankung (GERD) – in China angekündigt. „Wir sind hocherfreut, dass Mederi-Produkte nun auch in China erhältlich sind. Unsere Technologie, insbesondere Stretta für GERD, erfährt weltweit ein dramatisches Wachstum. Dieses Wachstum wird durch die Hauptvorteile klinischer Sicherheit und Wirksamkeit sowie durch die Vielseitigkeit und die geringeren Kosten von Stretta im Vergleich zu anderen GERD-Behandlungen gefördert. Stretta ist eine nicht-operative Technologie, die transoral angewendet wird und die Symptome von GERD reduziert, indem die Funktion des unteren Ösophagus-Sphinkters (UÖS) verbessert wird. Sie stellt eine ideale Alternative zu medikamentöser Behandlung und einer Operation bei chronischer GERD dar", erklärte Bob Knarr, Mederi CEO. „Eine Markteinführung in China, wo wir das Privileg eines exzellenten Vertriebspartners haben – Beijing Kanglian Medical – ist sehr aufregend." Die Stretta-Verfahren wurden kürzlich, während des Chinese Congress of Digestive Endoscopy, von Professor Jun Liu, Direktor für Endoskopie am Wuhan Union Hospital, durchgeführt und live übertragen. Zusätzlich wurde Stretta auch im Beijing General Army Hospital (301 Krankenhaus) durchgeführt. Dr. Enqiang Linghu, Chefarzt für Gastroenterologie am Beijing General Army Hospital, freut sich sehr, seinen an GERD leidenden Patienten Stretta anbieten zu können. „Hierbei handelt es sich um eine bewährte Lösung für Patienten, die trotz Medikamenteneinnahme weiterhin GERD-Symptome erfahren und eine Operation vermeiden möchten. Stretta wird für unsere Patienten eine wichtige Behandlungsoption sein, da wir viele dieser Patienten in unserem Krankenhaus sehen", bemerkte er. Wuman Zhang, Inhaber von Kanglian Medical, stimmt dem zu: „Stretta ist in der Lage, vielen verschiedenen GERD-Patienten zu helfen, einschließlich jener, die durch Medikamente nur eine unvollständige Linderung erfahren, extra-esophageale Symptome von Gerd erleben oder nach einer bariatrischen oder Anti-Reflux-Operation an GERD leiden. Chirurgen und Gastroenterologen in ganz China sehen der Möglichkeit, ihren Patienten Stretta anbieten zu können, ungeduldig entgegen." Studien zeigen, dass die Häufigkeit von GERD wie auch von Fettleibigkeit in China steigt. 2014 berichtete The Lancet, dass China weltweit nach den USA die zweithöchste Rate von Fettleibigkeit hat. Neben anderen ernsthafteren Komorbiditäten, wie Herzerkrankungen und Diabetes, tritt GERD prozentual häufiger bei der fettleibigen Bevölkerungsgruppe auf. Im Vergleich zu 10 - 20 Prozent für die Durchschnittsbevölkerung liegt hier die durchschnittliche Rate bei 60 - 70 Prozent. Außer in China erhielten Mederi-Produkte kürzlich international auch in folgenden Ländern eine behördliche Zulassung: Indien, Brasilien, Ägypten, Südkorea, Philippinen, Sri Lanka, Costa Rica und Panama. Mederi produziert innovative medizinische Geräte, die nicht ablative Radiofrequenz (RF) nutzen, um Erkrankungen des Verdauungsapparates zu behandeln. Die Sicherheit und Wirksamkeit der Stretta-Therapie zur Behandlung von GERD wurde in über 40 Studien nachgewiesen. Langfristige Folgestudien belegen eine zehn Jahre währende Symptomlinderung. Weltweit wurden über 25.000 Stretta-Behandlungen durchgeführt. Weitere Informationen erhalten Sie auf www.stretta-therapy.com oder in den USA telefonisch unter 855-855-3639.


News Article | December 8, 2016
Site: en.prnasia.com

NORWALK, Conn., Dec. 8, 2016 /PRNewswire/ -- Mederi Therapeutics Inc. has announced regulatory approval by CFDA and product launch in China for Stretta Therapy, a non-surgical treatment for chronic gastroesophageal reflux disease (GERD). "We are very pleased that Mederi products are now available in China. Our technology, especially Stretta for GERD, is experiencing dramatic growth worldwide. Driving this growth, are the key benefits of clinical safety and effectiveness, as well as the versatility and lower cost of Stretta compared to other GERD treatments. Stretta is a non-surgical technology, that is delivered transorally and reduces symptoms of GERD by improving lower esophageal sphincter (LES) function. It is an ideal alternative to medications and surgery for chronic GERD," stated Mederi CEO Bob Knarr. "It is very exciting to launch in China, where we are privileged to have an excellent distribution partner, Beijing Kanglian Medical." Stretta procedures were recently performed and broadcast live during the Chinese Congress of Digestive Endoscopy, by Professor Jun Liu, Director of Endoscopy at Wuhan Union Hospital, and Stretta was also performed at Beijing General Army Hospital (301 hospital). Dr. Enqiang Linghu, Chief of Gastroenterology at Beijing General Army Hospital is very pleased to offer Stretta to his patients dealing with GERD. "This is a proven solution for patients who still have GERD symptoms despite taking medications and want to avoid surgery. Stretta will be an important offering for our patient base as we see a lot these patients in our hospital," he noted. Wuman Zhang, principal of Kanglian Medical, agrees. "Stretta is positioned to help many kinds of chronic GERD patients, including those who have incomplete relief from medications, have extra-esophageal symptoms of GERD or have GERD after bariatric or anti-reflux surgery. Surgeons and gastroenterologists throughout China are eager to offer Stretta to their patients." Studies show that the prevalence of GERD as well as obesity, are on the rise in China. In 2014, The Lancet reported that China has the second highest obesity rate in the world, behind the United States. In addition to other more serious co-morbidities such as heart disease and diabetes, GERD is present in a much higher percentage of the obese population, at an average rate of 60-70 percent, versus 10-20 percent of the average population. In addition to China, other recent international regulatory approvals for Mederi products include: India, Brazil, Egypt, South Korea, Philippines, Sri Lanka, Costa Rica and Panama. Mederi manufactures innovative medical devices that use non-ablative radiofrequency (RF) energy to treat digestive diseases. Stretta Therapy for GERD, has been proven safe and effective for the treatment of GERD in more than 40 studies. Long-term follow up shows 10 years of durable symptom relief. More than 25,000 Stretta procedures have been performed worldwide. For more information go to: www.stretta-therapy.com, or in the U.S. call 855-855-3639.


News Article | December 8, 2016
Site: www.prnewswire.co.uk

Clinically proven and cost effective solution for gastroesophageal reflux disease recently launched in China. NORWALK, Connecticut, Dec. 8, 2016 /PRNewswire/ -- Mederi Therapeutics Inc. has announced regulatory approval by CFDA and product launch in China for Stretta Therapy, a non-surgical treatment for chronic gastroesophageal reflux disease (GERD). "We are very pleased that Mederi products are now available in China. Our technology, especially Stretta for GERD, is experiencing dramatic growth worldwide. Driving this growth, are the key benefits of clinical safety and effectiveness, as well as the versatility and lower cost of Stretta compared to other GERD treatments. Stretta is a non-surgical technology, that is delivered transorally and reduces symptoms of GERD by improving lower esophageal sphincter (LES) function. It is an ideal alternative to medications and surgery for chronic GERD," stated Mederi CEO Bob Knarr. "It is very exciting to launch in China, where we are privileged to have an excellent distribution partner, Beijing Kanglian Medical." Stretta procedures were recently performed and broadcast live during the Chinese Congress of Digestive Endoscopy, by Professor Jun Liu, Director of Endoscopy at Wuhan Union Hospital, and Stretta was also performed at Beijing General Army Hospital (301 hospital). Dr. Enqiang Linghu, Chief of Gastroenterology at Beijing General Army Hospital is very pleased to offer Stretta to his patients dealing with GERD. "This is a proven solution for patients who still have GERD symptoms despite taking medications and want to avoid surgery. Stretta will be an important offering for our patient base as we see a lot these patients in our hospital," he noted. Wuman Zhang, principal of Kanglian Medical, agrees. "Stretta is positioned to help many kinds of chronic GERD patients, including those who have incomplete relief from medications, have extra-esophageal symptoms of GERD or have GERD after bariatric or anti-reflux surgery. Surgeons and gastroenterologists throughout China are eager to offer Stretta to their patients." Studies show that the prevalence of GERD as well as obesity, are on the rise in China. In 2014, The Lancet reported that China has the second highest obesity rate in the world, behind the United States. In addition to other more serious co-morbidities such as heart disease and diabetes, GERD is present in a much higher percentage of the obese population, at an average rate of 60-70 percent, versus 10-20 percent of the average population. In addition to China, other recent international regulatory approvals for Mederi products include: India, Brazil, Egypt, South Korea, Philippines, Sri Lanka, Costa Rica and Panama. Mederi manufactures innovative medical devices that use non-ablative radiofrequency (RF) energy to treat digestive diseases. Stretta Therapy for GERD, has been proven safe and effective for the treatment of GERD in more than 40 studies. Long-term follow up shows 10 years of durable symptom relief. More than 25,000 Stretta procedures have been performed worldwide. For more information go to: www.stretta-therapy.com, or in the U.S. call 855-855-3639.


News Article | December 9, 2016
Site: www.prnewswire.co.uk

La solución para la enfermedad de reflujo gastrointestinal clínicamente demostrada y con un coste contenido se ha lanzado recientemente en China NORWALK, Connecticut, 9 de diciembre de 2016 /PRNewswire/ -- Mederi Therapeutics Inc. ha anunciado la aprobación normativa de CFDA y el lanzamiento de producto en China para la terapia Stretta, un tratamiento no quirúrgico para enfermedad crónica de reflujo gastroesofágico (GERD). "Estamos muy contentos de que los productos de Mederi ya están disponibles en China. Nuestra tecnología, sobre todo Stretta para GERD, está experimentando un crecimiento enorme en todo el mundo. Lo que impulsa este crecimiento son los beneficios destacados de la seguridad clínica y la eficacia, además de la versatilidad y el bajo coste de Stretta frente a otros tratamientos para GERD. La terapia Stretta es una tecnología no quirúrgica que se suministra de modo transoral y reduce los síntomas de GERD al mejorar la función del esfínter esofágico bajo (LES). Es una alternativa ideal a los medicamentos y a la cirugía para GERD crónica", explicó el consejero delegado de Mederi, Bob Knarr. "Es muy emocionante llevar a cabo su lanzamiento en China, donde disponemos del privilegio de contar con un excelente socio de distribución, Beijing Kanglian Medical". Los procedimientos de Stretta se realizaron recientemente y fueron emitidos en directo durante la celebración del Chinese Congress of Digestive Endoscopy, por el profesor Jun Liu, director de Endoscopia del Wuhan Union Hospital, mientras que la terapia Stretta también se probó en el Beijing General Army Hospital (hospital 301). El doctor Enqiang Linghu, responsable de Gastroenterología del Beijing General Army Hospital, se mostró muy contento de poder ofrecer la terapia Stretta a sus pacientes que padecen GERD. "Se trata de una solución demostrada para pacientes que aún padecen síntomas de GERD pese a que toman medicamentos y que buscan evitar la cirugía. Stretta va a ser una oferta importante de cara a nuestra base de pacientes, ya que existe una cantidad importante de pacientes en nuestro hospital", comentó. Wuman Zhang, director de Kanglian Medical, se mostró de acuerdo con ello. "Stretta se ha posicionado para ayudar a muchos tipos de pacientes con GERD crónica, incluyendo a los que no notan un alivio completo por medio de los medicamentos, los que presentan síntomas extraesofágicos de GERD o sufren GERD tras someterse a una cirugía bariátrica o anti-reflujo. Los cirujanos y gastroenterologistas de China están impacientes por ofrecer a sus pacientes Stretta". Hay estudios que han demostrado que la prevalencia de GERD y la obesidad están en auge en China. En el año 2014, The Lancet informó de que China tenía la segunda mayor tasa de obesidad a nivel mundial, por detrás de los Estados Unidos. Además de otras comorbilidades más graves, como por ejemplo enfermedades cardíacas y diabetes, GERD está presente en un porcentaje mucho mayor entre la población obesa, con una tasa media de entre el 60% y el 70%, en comparación con el 10% y el 20% de la población media. Además de China, otras de las aprobaciones normativas recientes a nivel internacional para los productos Mederi incluyen: La India, Brasil, Egipto, Corea del Sur, Filipinas, Sri Lanka, Costa Rica y Panamá. Mederi fabrica dispositivos médicos innovadores que usan la energía no ablativa de radiofrecuencia (RF) para llevar a cabo el tratamiento de las enfermedades digestivas. La terapia Stretta para GERD ha demostrado su seguridad y eficacia para el tratamiento de la GERD en más de 40 estudios. El seguimiento a largo plazo ha mostrado hasta 10 años del alivio duradero de los síntomas. A nivel mundial se han llevado a cabo más de 25.000 procedimientos con Stretta. Si desea más información visite: www.stretta-therapy.com, o en Estados Unidos llame al 855-855-3639.


PubMed | Digestive Endoscopy
Type: Journal Article | Journal: Diagnostic and interventional imaging | Year: 2016

Computed tomography (CT) and endoscopic ultrasound (EUS) are the two most effective techniques for the assessment of pancreatic cancers. CT has revolutionized the field of tumor imaging in pancreatic cancer and is now a well-established imaging technique for diagnosis and staging. However, EUS still plays an important role in several situations, especially when the diagnosis is uncertain or when histopathological confirmation of the lesion is needed. Similarly, regarding cystic lesions, magnetic resonance imaging and CT have very good performances but are often inadequate because the diagnosis can be difficult to establish, while the consequences for the patient are major. New biopsy needles, the use of elastography and ultrasonographic contrast agents, and confocal laser endomicroscopy can also provide additional and essential information to improve diagnosis confidence of pancreatic lesions with EUS.

Loading Digestive Endoscopy collaborators
Loading Digestive Endoscopy collaborators